Journal
BIO-PROTOCOL
Volume 12, Issue 15, Pages -Publisher
BIO-PROTOCOL
DOI: 10.21769/BioProtoc.4485
Keywords
CRISPR-Cas9; TCR knockout; CD3 negative selection; orthoCAR T cells; TRAC; TRBC guide RNA; 4D-Nucleofector Lonza Electroporator
Categories
Ask authors/readers for more resources
Genome-editing technologies like CRISPR/Cas9 play a crucial role in improving CAR T cell immunotherapy. This article presents an optimized approach that applies CRISPR/Cas9 to human T cells, knocking out TCR alpha and TCR beta genes to completely eliminate T cell receptor protein expression. This method may have potential applications in targeted therapies for other cell surface receptors.
Genome-editing technologies, especially CRISPR (clustered regularly interspaced short palindrome repeats)/Cas9 (CRISPR-associated protein 9), endows researchers the ability to make efficient, simple, and precise genomic DNA changes in many eukaryotic cell types. CRISPR/Cas9-mediated efficient gene knockout holds huge potential to improve the efficacy and safety of chimeric antigen receptor (CAR) T cell-based immunotherapies. Here, we describe an optimized approach for a complete loss of endogenous T cell receptor (TCR) protein expression, by CRISPR/Cas9-mediated TCR alpha constant (TRAC) and TCR beta constant (TRBC) gene knockout, followed by subsequent CD3 negative selection in engineered human orthoCAR19 T cells. We believe this method can be expanded beyond CAR T cell application, and target other cell surface receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available